Study Purpose: This study aims to find a safe and effective dose of a new drug, BMS-986393, for patients with a type of blood cancer called multiple myeloma. This cancer has come back or does not respond to treatment, which is called relapsed or refractory. The study will combine BMS-986393 with other drugs, alnuctamab, mezigdomide, and iberdomide.

Who Can Join: Adults with relapsed or refractory multiple myeloma who have had at least one to three treatments for their cancer before. They must have cancer that can be measured and be in good physical health (able to do normal activities). People cannot join if they have brain or spinal cord involvement from their cancer.

• **Participation Length:** Varies, based on treatment response.
• **Compensation:** Available for travel and participation.
• **Risks:** Potential side effects from drug combinations.

This study is looking to understand the safest way to help those with difficult-to-treat multiple myeloma.